PSA Dynamics Predict Metastatic Castration-Sensitive Prostate Cancer Treatment Outcomes – Renal and Urology News
Adding abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) significantly increases the magnitude and depth of PSA responses in patients with high-risk metastatic castration-sensitive prostate cancer (mCSPC), and this correlates strongly with improved radiographic progression-free and overall survival, investigators concluded. The finding is from a post hoc analysis of…
